Systematic review of antimicrobial lock therapy for prevention of central-line-associated bloodstream infections in adult and pediatric cancer patients

International Journal of Antimicrobial Agents

Volumn 50, Issue 3, 2017, Pages 308-317

  Norris, LeAnn B ^a   Kablaoui, Farah ^b   Brilhart, Maggie K ^c   Bookstaver, P Brandon ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b HEART AND VASCULAR INSTITUTE   (United Arab Emirates)

^c WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

Antimicrobial lock therapy; Catheter related bloodstream infections; Central venous catheters; Central line associated bloodstream infection

Indexed keywords

ALCOHOL; ANTIINFECTIVE AGENT; CIPROFLOXACIN; EDETIC ACID; HEPARIN; MINOCYCLINE; TAUROLIDINE; VANCOMYCIN;

ADULT; ANTIMICROBIAL LOCK THERAPY; ANTIMICROBIAL THERAPY; BACTERIUM CULTURE; BLUSHING; CANCER PATIENT; CASE CONTROL STUDY; CASE STUDY; CATHETER INFECTION; CHILD; COHORT ANALYSIS; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG UTILIZATION; DYSESTHESIA; EVIDENCE BASED MEDICINE; GRAM POSITIVE INFECTION; HUMAN; IN VITRO STUDY; INCIDENCE; INFECTION PREVENTION; MEDICAL RESEARCH; META ANALYSIS; NAUSEA; NONHUMAN; OBSERVATIONAL STUDY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; THORAX PAIN; CENTRAL VENOUS CATHETERIZATION; COMPLICATION; NEOPLASM; PROCEDURES; SEPSIS; TREATMENT OUTCOME;

ANTI-INFECTIVE AGENTS; CATHETER-RELATED INFECTIONS; CATHETERIZATION, CENTRAL VENOUS; HUMANS; NEOPLASMS; SEPSIS; TREATMENT OUTCOME;

EID: 85026304745     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2017.06.013     Document Type: Review

References (56)

1. O'Grady, N.P., Alexander, M., Burns, L.A., Dellinger, E.P., Garland, J., Heard, S.O., et al. Guidelines for the prevention of intravascular catheter-related infections. Am J Infect Control 39 (2011), S1–34.
2. Centers for Disease Control and Prevention, Vital signs: central line-associated blood stream infections – United States, 2001, 2008, and 2009. MMWR 60 (2011), 243–248.
3. Wisplinghoff, H., Bischoff, T., Tallent, S.M., Seifert, H., Wenzel, R.P., Edmond, M.B., Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39 (2004), 309–317.
4. Butt, T., Afzal, R.K., Ahmad, R.N., Salman, M., Mahmood, A., Anwar, M., Bloodstream infections in febrile neutropenic patients: bacterial spectrum and antimicrobial susceptibility pattern. J Ayub Med Coll Abbottabad 16 (2004), 18–22.
5. Celebi, S., Sezgin, M.E., Cakir, D., Baytan, B., Demirkaya, M., Sevinir, B., et al. Catheter-associated bloodstream infections in pediatric hematology-oncology patients. Pediatr Hematol Oncol 30 (2013), 187–194.
6. Crnich, C.J., Estimating excess length of stay due to central line-associated bloodstream infection: separating the wheat from the chaff. Infect Control Hosp Epidemiol 31 (2010), 1115–1117.
7. Wolf, J., Shenep, J.L., Clifford, V., Curtis, N., Flynn, P.M., Ethanol lock therapy in pediatric hematology and oncology. Pediatr Blood Cancer 60 (2013), 18–25.
8. Sanders, J., Pithie, A., Ganly, P., Surgenor, L., Wilson, R., Merriman, E., et al. A prospective double-blind randomized trial comparing intraluminal ethanol with heparinized saline for the prevention of catheter-associated bloodstream infection in immunosuppressed haematology patients. J Antimicrob Chemother 62 (2008), 809–815.
9. Miller, A., Hospital reporting and ‘never events’. Medicare Pat Manag 4 (2009), 20–22.
10. Scott, R.D., The direct medical costs of healthcare-associated infections in US hospitals and the benefits of prevention. Atlanta, GA: Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention; Available from: http://www.cdc.gov/HAI/pdfs/hai/Scott_CostPaper.pdf, 2009 [Accessed 9 November 2015].
11. van de Wetering, M.D., van Woensel, J.B., Prophylactic antibiotics for preventing early central venous catheter Gram positive infections in oncology patients. Cochrane Database Syst Rev(1), 2007 CD003295.
12. Butt, T., Afzal, R.K., Ahmad, R.N., Hussain, I., Anwar, M., Central venous catheter-related bloodstream infections in cancer patients. J Coll Phys Surg Pakistan 14 (2004), 549–552.
13. Manierski, C., Besarab, A., Antimicrobial locks: putting the lock on catheter infections. Adv Chron Kid Dis 13 (2006), 245–258.
14. Bookstaver, P.B., Williamson, J.C., Tucker, B.K., Raad, I.I., Sherertz, R.J., Activity of novel antibiotic lock solutions in a model against isolates of catheter-related bloodstream infections. Ann Pharmacother 43 (2009), 210–219.
15. Safdar, N., Maki, D.G., Use of vancomycin-containing lock or flush solutions for prevention of bloodstream infection associated with central venous access devices: a meta-analysis of prospective, randomized trials. Clin Infect Dis 43 (2006), 474–484.
16. Mermel, L.A., Allon, M., Bouza, E., Craven, D.E., Flynn, P., O'Grady, N.P., et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 49 (2009), 1–45.
17. National Comprehensive Cancer Network, National Comprehensive Cancer Network guidelines for the management of prostate cancer. Fort Washington, PA: NCCN, 2015.
18. Schiffer, C.A., Mangu, P.B., Wade, J.C., Camp-Sorrell, D., Cope, D.G., El-Rayes, B.F., et al. Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 31 (2013), 1357–1370.
19. Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. System Rev, 4, 2015, 1.
20. Andrews, J.C., Schunemann, H.J., Oxman, A.D., Pottie, K., Meerpohl, J.J., Coello, P.A., et al. GRADE guidelines: 15. Going from evidence to recommendation – determinants of a recommendation's direction and strength. J Clin Epidemiol 66 (2013), 726–735.
21. Carratala, J., Niubo, J., Fernandez-Sevilla, A., Juve, E., Castellsague, X., Berlanga, J., et al. Randomized, double-blind trial of an antibiotic-lock technique for prevention of Gram-positive central venous catheter-related infection in neutropenic patients with cancer. Antimicrob Agents Chemother 43 (1999), 2200–2204.
22. Slobbe, L., Doorduijn, J.K., Lugtenburg, P.J., El Barzouhi, A., Boersma, E., van Leeuwen, W.B., et al. Prevention of catheter-related bacteremia with a daily ethanol lock in patients with tunnelled catheters: a randomized, placebo-controlled trial. PLoS ONE, 5, 2010, e10840.
23. Schoot, R.A., van Ommen, C.H., Stijnen, T., Tissing, W.J., Michiels, E., Abbink, F.C., et al. Prevention of central venous catheter-associated bloodstream infections in paediatric oncology patients using 70% ethanol locks: a randomised controlled multi-centre trial. Eur J Cancer 51 (2015), 2031–2038.
24. Schwartz, C., Henrickson, K.J., Roghmann, K., Powell, K., Prevention of bacteremia attributed to luminal colonization of tunneled central venous catheters with vancomycin-susceptible organisms. J Clin Oncol 8 (1990), 1591–1597.
25. Rackoff, W.R., Weiman, M., Jakobowski, D., Hirschl, R., Stallings, V., Bilodeau, J., et al. A randomized, controlled trial of the efficacy of a heparin and vancomycin solution in preventing central venous catheter infections in children. J Pediatr 127 (1995), 147–151.
26. Barriga, F.J., Varas, M., Potin, M., Sapunar, F., Rojo, H., Martinez, A., et al. Efficacy of a vancomycin solution to prevent bacteremia associated with an indwelling central venous catheter in neutropenic and non-neutropenic cancer patients. Med Pediatr Oncol 28 (1997), 196–200.
27. Chatzinikolaou, I., Zipf, T.F., Hanna, H., Umphrey, J., Roberts, W.M., Sherertz, R., et al. Minocycline-ethylenediaminetetraacetate lock solution for the prevention of implantable port infections in children with cancer. Clin Infect Dis 36 (2003), 116–119.
28. Daghistani, D., Horn, M., Rodriguez, Z., Schoenike, S., Toledano, S., Prevention of indwelling central venous catheter sepsis. Med Pediatr Oncol 26 (1996), 405–408.
29. Henrickson, K.J., Axtell, R.A., Hoover, S.M., Kuhn, S.M., Pritchett, J., Kehl, S.C., et al. Prevention of central venous catheter-related infections and thrombotic events in immunocompromised children by the use of vancomycin/ciprofloxacin/heparin flush solution: a randomized, multicenter, double-blind trial. J Clin Oncol 18 (2000), 1269–1278.
30. Simon, A., Ammann, R.A., Wiszniewsky, G., Bode, U., Fleischhack, G., Besuden, M.M., Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients. BMC Infect Dis, 8, 2008, 102.
31. Dumichen, M.J., Seeger, K., Lode, H.N., Kuhl, J.S., Ebell, W., Degenhardt, P., et al. Randomized controlled trial of taurolidine citrate versus heparin as catheter lock solution in paediatric patients with haematological malignancies. J Hosp Infect 80 (2012), 304–309.
32. Handrup, M.M., Moller, J.K., Schroder, H., Central venous catheters and catheter locks in children with cancer: a prospective randomized trial of taurolidine versus heparin. Pediatr Blood Cancer 60 (2013), 1292–1298.
33. Handrup, M.M., Fuursted, K., Funch, P., Moller, J.K., Schroder, H., Biofilm formation in long-term central venous catheters in children with cancer: a randomized controlled open-labelled trial of taurolidine versus heparin. APMIS 120 (2012), 794–801.
34. Rubie, H., Juricic, M., Claeyssens, S., Krimou, A., Lemozy, J., Izard, P., et al. Morbidity using subcutaneous ports and efficacy of vancomycin flushing in cancer. Arch Dis Child 72 (1995), 325–329.
35. Steinberg, J.P., Robichaux, C., Tejedor, S.C., Reyes, M.D., Jacob, J.T., Distribution of pathogens in central line-associated bloodstream infections among patients with and without neutropenia following chemotherapy: evidence for a proposed modification to the current surveillance definition. Infect Control Hosp Epidemiol 34 (2013), 171–175.
36. Dudeck, M.A., Weiner, L.M., Allen-Bridson, K., Malpiedi, P.J., Peterson, K.D., Pollock, D.A., et al. National Healthcare Safety Network (NHSN) report, data summary for 2012, device-associated module. Am J Infect Control 41 (2013), 1148–1166.
37. Raad, I., Buzaid, A., Rhyne, J., Hachem, R., Darouiche, R., Safar, H., et al. Minocycline and ethylenediaminetetraacetate for the prevention of recurrent vascular catheter infections. Clin Infect Dis 25 (1997), 149–151.
38. Bookstaver, P.B., Rokas, K.E., Norris, L.B., Edwards, J.M., Sherertz, R.J., Stability and compatibility of antimicrobial lock solutions. Am J Health Syst Pharm 70 (2013), 2185–2198.
39. Maiefski, M., Rupp, M.E., Hermsen, E.D., Ethanol lock technique: review of the literature. Infect Control Hosp Epidemiol 30 (2009), 1096–1108.
40. Takla, T.A., Zelenitsky, S.A., Vercaigne, L.M., Effect of ethanol/trisodium citrate lock on microorganisms causing hemodialysis catheter-related infections. J Vasc Access 8 (2007), 262–267.
41. Mahieu, L.M., De Dooy, J.J., Lenaerts, A.E., Ieven, M.M., De Muynck, A.O., Catheter manipulations and the risk of catheter-associated bloodstream infection in neonatal intensive care unit patients. J Hosp Infect 48 (2001), 20–26.
42. Kayton, M.L., Garmey, E.G., Ishill, N.M., Cheung, N.K., Kushner, B.H., Kramer, K., et al. Preliminary results of a phase I trial of prophylactic ethanol-lock administration to prevent mediport catheter-related bloodstream infections. J Pediatr Surg 45 (2010), 1961–1966.
43. Cober, M.P., Johnson, C.E., Stability of 70% alcohol solutions in polypropylene syringes for use in ethanol-lock therapy. Am J Health Syst Pharm 64 (2007), 2480–2482.
44. Pomplun, M., Johnson, J.J., Johnston, S., Kolesar, J.M., Stability of a heparin-free 50% ethanol lock solution for central venous catheters. J Oncol Pharm Pract 13 (2007), 33–37.
45. Raucher, H.S., Hyatt, A.C., Barzilai, A., Harris, M.B., Weiner, M.A., LeLeiko, N.S., et al. Quantitative blood cultures in the evaluation of septicemia in children with Broviac catheters. J Pediatr 104 (1984), 29–33.
46. Raad, I.I., Hachem, R.Y., Hanna, H.A., Fang, X., Jiang, Y., Dvorak, T., et al. Role of ethylene diamine tetra-acetic acid (EDTA) in catheter lock solutions: EDTA enhances the antifungal activity of amphotericin B lipid complex against candida embedded in biofilm. Int J Antimicrob Agents 32 (2008), 515–518.
47. Beutel, K., Simon, A., [Diagnostics and management of central venous line infections in pediatric cancer patients]. Klin Padiatr 217:Suppl. 1 (2005), S91–100.
48. Zwiech, R., Adelt, M., Chrul, S., A taurolidine-citrate-heparin lock solution effectively eradicates pathogens from the catheter biofilm in hemodialysis patients. Am J Ther 23 (2016), e363–8.
49. http://www.taurolock.com/en/download/brochure [Accessed 9 December 2016].
50. Liu, Y., Zhang, A.Q., Cao, L., Xia, H.T., Ma, J.J., Taurolidine lock solutions for the prevention of catheter-related bloodstream infections: a systematic review and meta-analysis of randomized controlled trials. PLoS ONE, 8, 2013, e79417.
51. Rosenthal, V.D., Guzman, S., Migone, O., Crnich, C.J., The attributable cost, length of hospital stay, and mortality of central line-associated bloodstream infection in intensive care departments in Argentina: a prospective, matched analysis. Am J Infect Control 31 (2003), 475–480.
52. Pittet, D., Tarara, D., Wenzel, R.P., Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA 271 (1994), 1598–1601.
53. Justo, J.A., Bookstaver, P.B., Antibiotic lock therapy: review of technique and logistical challenges. Infect Drug Resist 7 (2014), 343–363.
54. Perez-Granda, M.J., Barrio, M.J., Munoz, P., Hortal, J., Rincon, C., Rabadan, P.M., et al. Ethanol lock therapy (E-Lock) in the prevention of catheter-related bloodstream infections (CR-CSI) after major heart surgery (MHS): a randomized clinical trial. PLoS ONE, 9, 2014 e91838.
55. Souweine, B., Lautrette, A., Gruson, D., Canet, E., Klouche, K., Argaud, L., et al. Ethanol lock and risk of hemodialysis catheter infection in critically ill patients. A randomized controlled trial. Am J Respir Crit Care Med 191 (2015), 1024–1032.
56. Committee on Drugs, Ethanol in liquid preparations intended for children. Pediatrics 73 (1984), 405–407.